The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (T2DM)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Byetta (exenatide)
Symlin (pramlintide)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Diabetes, pramlintide, Symlin, exenatide, byetta, glucagon, gastric emptying
Eligibility Criteria
Inclusion Criteria:
- Children with Type 2 Diabetes,
- Between the ages of 12-21 years,
- Tanner stage 4-5 for pubertal development,
- Menstruating females must have a negative urine pregnancy test for inclusion,
- Must have T2DM for at least 6 months,
- History of negative anti-glutamic acid decarboxylase (GAD) -65 and anti-islet cell antibodies,
- HbA1c < 8.5% and on a stable dose of an oral hypoglycemic agent (with or without insulin) over the last 2 months, or well controlled on diet.
Exclusion Criteria:
- A history of a chronic disease other than diabetes (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, dyslipidemia, cholelithiasis etc),
- BMI> 40 kg/m2,
- Weight of < 60 kg,
- Female with menstrual irregularities,
- Allergy to local anesthetics (ELAMAX Cream, Ethyl Chloride),
- Evidence or history of chemical abuse,
- Anemia (age specific normal range for hemoglobin will be used),
- Elevated liver enzymes (defined as more than 3 times the upper limit of the normal range for age),
- Elevated BUN or creatinine (defined as more than 3 times the upper limit of the normal range for age),
- Use of medications that may increase the blood sugars and admission to the hospital for diabetes related problems over the last 6 months.
Sites / Locations
- Baylor College of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
exenatide
pramlintide
Arm Description
exenatide one dose
pramlintide one dose
Outcomes
Primary Outcome Measures
Glucose
concentration and AUC calculations
Secondary Outcome Measures
glucagon
concentration and AUC calculations
gastric emptying
concentration and AUC calculations
pramlintide concentrations
concentration and AUC calculations
exenatide concentrations
concentration and AUC calculations
Full Information
NCT ID
NCT00950677
First Posted
July 30, 2009
Last Updated
April 21, 2017
Sponsor
Baylor College of Medicine
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT00950677
Brief Title
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
Acronym
T2DM
Official Title
The Effect of the Glucagon Suppressors Pramlintide and Exenatide on Postprandial Glucose Metabolism in Children With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
May 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to see if giving study drugs before a meal may lower blood sugars after the meal. An improvement in blood sugar control may prevent long-term problems of diabetes.
Detailed Description
A large study in people with type 2 diabetes (T2DM) showed that lowering blood sugars stopped or delayed the occurrence of health problems. As a result of the study, treatment should try to control blood sugars as near to normal as safely possible.
In people without diabetes, the "after meal" blood sugar level is very carefully controlled by several hormones. Insulin (the hormone that lowers blood sugar) and glucagon (hormone that raises blood sugar) play a key role in keeping this careful balance. Also, we now know of 2 new substances made by the body called amylin and GLP-1 that also help with this careful balance. Amylin is made in the pancreas. GLP-1 is made in the gut. We know that both amylin and GLP-1 are abnormal in people with diabetes.
There are two medicines that may help to control after meal blood sugars from going too high. The medicines are called Symlin (pramlintide) and Byetta (exenatide). Symlin works like amylin. Byetta works like GLP-1. Both medications are very similar in the ways that they work to control blood sugars.
Both medicines help to keep glucagon lower after a meal. They both also help the stomach to digest food more slowly so the blood sugar does not go up too fast after eating. They also help to control how much hunger a person may have before meals. This may help a person to eat less and possibly lose weight. Byetta also seems to help islet cells (cells that make insulin) make more insulin.
Byetta and Symlin are FDA approved for use in adults with T2DM. We want to study these drugs in children with T2DM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Diabetes, pramlintide, Symlin, exenatide, byetta, glucagon, gastric emptying
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
exenatide
Arm Type
Active Comparator
Arm Description
exenatide one dose
Arm Title
pramlintide
Arm Type
Active Comparator
Arm Description
pramlintide one dose
Intervention Type
Drug
Intervention Name(s)
Byetta (exenatide)
Intervention Description
exenatide 5 mcg subcutaneously
Intervention Type
Drug
Intervention Name(s)
Symlin (pramlintide)
Intervention Description
pramlintide 60 mcg subcutaneously
Primary Outcome Measure Information:
Title
Glucose
Description
concentration and AUC calculations
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
glucagon
Description
concentration and AUC calculations
Time Frame
4 hrours
Title
gastric emptying
Description
concentration and AUC calculations
Time Frame
4 hours
Title
pramlintide concentrations
Description
concentration and AUC calculations
Time Frame
4 hours
Title
exenatide concentrations
Description
concentration and AUC calculations
Time Frame
4 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children with Type 2 Diabetes,
Between the ages of 12-21 years,
Tanner stage 4-5 for pubertal development,
Menstruating females must have a negative urine pregnancy test for inclusion,
Must have T2DM for at least 6 months,
History of negative anti-glutamic acid decarboxylase (GAD) -65 and anti-islet cell antibodies,
HbA1c < 8.5% and on a stable dose of an oral hypoglycemic agent (with or without insulin) over the last 2 months, or well controlled on diet.
Exclusion Criteria:
A history of a chronic disease other than diabetes (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, dyslipidemia, cholelithiasis etc),
BMI> 40 kg/m2,
Weight of < 60 kg,
Female with menstrual irregularities,
Allergy to local anesthetics (ELAMAX Cream, Ethyl Chloride),
Evidence or history of chemical abuse,
Anemia (age specific normal range for hemoglobin will be used),
Elevated liver enzymes (defined as more than 3 times the upper limit of the normal range for age),
Elevated BUN or creatinine (defined as more than 3 times the upper limit of the normal range for age),
Use of medications that may increase the blood sugars and admission to the hospital for diabetes related problems over the last 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
LUISA M RODRIGUEZ, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
We'll reach out to this number within 24 hrs